Septerna (NASDAQ:SEPN) Trading Down 6.6% - Here's Why

Key Points

• Septerna, Inc. (NASDAQ:SEPN) shares fell by 6.6% to $12.91, marking a significant decline in mid-day trading with volume down by 80% compared to the average session.
• Analyst ratings remain mixed; while HC Wainwright has a "buy" rating with a price target of $26.00, other firms suggest more conservative targets between $18.00 and $25.00.
• The company's recent quarterly earnings report showed a loss of ($0.49) per share, falling short of analysts' expectations, with expected EPS of -7.11 for the current fiscal year.

Septerna, Inc. (NASDAQ:SEPN - Get Free Report) shares fell 6.6% on Tuesday . The stock traded as low as $12.25 and last traded at $12.91. 142,574 shares traded hands during mid-day trading, a decline of 80% from the average session volume of 730,508 shares. The stock had previously closed at $13.83.

Wall Street Analyst Weigh In

Several research firms have weighed in on SEPN. HC Wainwright started coverage on shares of Septerna in a research report on Monday, June 23rd. They issued a "buy" rating and a $26.00 price target on the stock. Wells Fargo & Company lifted their target price on Septerna from $11.00 to $18.00 and gave the stock an "equal weight" rating in a report on Friday, May 16th. Finally, Cantor Fitzgerald lifted their price objective on shares of Septerna from $20.00 to $25.00 and gave the stock an "overweight" rating in a research note on Friday, May 16th. One investment analyst has rated the stock with a hold rating and four have given a buy rating to the company's stock. According to MarketBeat, the stock has an average rating of "Moderate Buy" and an average price target of $26.75.

Septerna Price Performance

The firm's 50-day moving average price is $10.91 and its two-hundred day moving average price is $9.63.

Septerna (NASDAQ:SEPN - Get Free Report) last issued its quarterly earnings results on Thursday, May 15th. The company reported ($0.49) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.38) by ($0.11). The business had revenue of $0.22 million for the quarter. As a group, research analysts expect that Septerna, Inc. will post -7.11 earnings per share for the current fiscal year.

Institutional Trading of Septerna

Several large investors have recently made changes to their positions in the business. Bank of America Corp DE purchased a new position in Septerna during the fourth quarter valued at $1,803,000. JPMorgan Chase & Co. purchased a new position in Septerna during the fourth quarter valued at $871,000. Jane Street Group LLC purchased a new position in Septerna during the fourth quarter valued at $600,000. MetLife Investment Management LLC purchased a new position in Septerna during the fourth quarter valued at $265,000. Finally, Barclays PLC purchased a new position in Septerna during the fourth quarter valued at $659,000.

Septerna Company Profile

We are a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by our proprietary Native Complex Platform™. Our industrial-scale platform aims to unlock the full potential of GPCR therapies and has led to the discovery and development of our deep pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.